Currently, there are 193.87M common shares owned by the public and among those 173.22M shares have been available to trade.
The company’s stock has a 5-day price change of 17.85% and 4.99% over the past three months. OSCR shares are trading 97.70% year to date (YTD), with the 12-month market performance up to 228.31% higher. It has a 12-month low price of $5.30 and touched a high of $23.79 over the same period. OSCR has an average intraday trading volume of 2.99 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.45%, -3.43%, and 4.74% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Oscar Health Inc (NYSE: OSCR) shares accounts for 59.41% of the company’s 193.87M shares outstanding.
It has a market capitalization of $4.60B and a beta (3y monthly) value of 1.66. The earnings-per-share (ttm) stands at -$0.13. The company has a debt-to-equity ratio at 0.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.64% over the week and 6.39% over the month.
Analysts forecast that Oscar Health Inc (OSCR) will achieve an EPS of -0.17 for the current quarter, -0.57 for the next quarter and 0.59 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.23 while analysts give the company a high EPS estimate of -0.23. Comparatively, EPS for the current quarter was -0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 105.05%, and 863.96% over the next financial year. EPS should grow at an annualized rate of 71.00% over the next five years, compared to -2.85% over the past 5-year period.
Looking at the support for the OSCR, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on October 07, 2024, with the firm’s price target at $23. Piper Sandler coverage for the Oscar Health Inc (OSCR) stock in a research note released on June 26, 2024 offered a Overweight rating with a price target of $25. Robert W. Baird was of a view on May 30, 2024 that the stock is Outperform, while BofA Securities gave the stock Neutral rating on May 30, 2024, issuing a price target of $25- $21. Raymond James on their part issued Outperform rating on March 22, 2024.
